Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries
HANGZHOU, China and SHAOXING, China, Feb. 13, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in Germany, France, Ireland and United Kingdom through its agent in…
Comments Off on Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries